Jio Financial Services partners with Allianz for new reinsurance venture

Oliver Bäte Chairman of the Board of Management of Allianz SE (CEO) Allianz SE
Oliver Bäte Chairman of the Board of Management of Allianz SE (CEO) - Allianz SE
0Comments

Jio Financial Services Limited and Allianz have announced plans to establish a 50:50 reinsurance joint venture. The collaboration aims to leverage the strengths of both companies in the insurance sector.

Allianz Group, recognized as one of the leading insurers and asset managers globally, serves approximately 128 million private and corporate customers across nearly 70 countries. The company’s services include property, life, health insurance, assistance services, credit insurance, and global business insurance.

Allianz is also noted for its significant investment activities. It manages around 768 billion euros on behalf of its insurance clients. Additionally, its asset management arms—PIMCO and Allianz Global Investors—handle approximately 1.9 trillion euros in third-party assets.

The company integrates ecological and social criteria into its business processes and investment decisions. This approach has positioned Allianz as a leader in the Dow Jones Sustainability Index within the insurance industry.

In 2024, Allianz employed over 156,000 people who generated a total business volume of 179.8 billion euros and an operating profit of 16.0 billion euros for the group.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.